fashion -WSS

fashion

author：leisure time 2025-09-27 19:49:57 - browse：55

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Lecanemab for Alzheimer's is coming. Is the health system ready?

WSS

Lecanemab for Alzheimer's is coming. Is the health system ready?

Retired US general questions alleged Putin, Prigozhin meeting

Biden launches a new push to limit health care costs

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

STAT Readout Newsletter: Biotech news today

Retired US general questions alleged Putin, Prigozhin meeting

explore

fashion

explore

As demand for Covid shots wanes, Moderna seeks its next success

Why 40% Americans with Parkinson’s don’t see a neurologist

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

It's time to get medical device identifiers over the finish line

Virginia high school admissions case could be legal follow

California’s proposed $25 per hour health care minimum wage

23andMe had bad news about my health. I wish a person had delivered it

Merck, Daiichi strike cancer drug pact worth up to $22 billion

George Santos makes 1st court appearance after pleading not guilty to 13 counts

New research casts further doubt on a common procedure used with IVF

focus

FDA clears Verve to begin U.S. study of gene

How the political right came to back psychedelics to treat trauma

CZI to create biohub to build anti

Iowa House, Senate pass 6

A new study sees potential in DNA sequencing of infants

Roche acquires Telavant from Roivant, adding experimental IBD treatment

leisure time

hotspot

explore

entertainment